These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 10495852

  • 1. [Development and establishment of a yeast-based stop codon assay for detection of NF2 gene premature-terminating mutations].
    Kobayashi H.
    Hokkaido Igaku Zasshi; 1999 Sep; 74(5):377-86. PubMed ID: 10495852
    [Abstract] [Full Text] [Related]

  • 2. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
    Koga H, Araki N, Takeshima H, Nishi T, Hirota T, Kimura Y, Nakao M, Saya H.
    Oncogene; 1998 Aug 20; 17(7):801-10. PubMed ID: 9779996
    [Abstract] [Full Text] [Related]

  • 3. [Neurofibromatosis type 2 (NF2)].
    Araki N, Takeshima H, Saya H.
    Gan To Kagaku Ryoho; 1997 Sep 20; 24(11):1427-31. PubMed ID: 9309136
    [Abstract] [Full Text] [Related]

  • 4. [Development of a detection system (APC yeast color assay) of APC mutations by color change of yeast].
    Furuuchi K.
    Hokkaido Igaku Zasshi; 2000 Nov 20; 75(6):385-97. PubMed ID: 11193931
    [Abstract] [Full Text] [Related]

  • 5. [Detectability and diagnostic criteria of p53 gene mutations in human oral squamous cell carcinoma using yeast functional assay].
    Kashiwazaki H.
    Hokkaido Igaku Zasshi; 1997 Mar 20; 72(2):211-24. PubMed ID: 9145313
    [Abstract] [Full Text] [Related]

  • 6. Screening for large mutations of the NF2 gene.
    Kluwe L, Nygren AO, Errami A, Heinrich B, Matthies C, Tatagiba M, Mautner V.
    Genes Chromosomes Cancer; 2005 Apr 20; 42(4):384-91. PubMed ID: 15645494
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Detection of novel NF2 mutations by an RNA mismatch cleavage method.
    Faudoa R, Xue Z, Lee F, Baser ME, Hung G.
    Hum Mutat; 2000 Apr 20; 15(5):474-8. PubMed ID: 10790209
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene?
    Bruder CE, Ichimura K, Blennow E, Ikeuchi T, Yamaguchi T, Yuasa Y, Collins VP, Dumanski JP.
    Genes Chromosomes Cancer; 1999 Jun 20; 25(2):184-90. PubMed ID: 10338003
    [Abstract] [Full Text] [Related]

  • 14. Further genotype--phenotype correlations in neurofibromatosis 2.
    Selvanathan SK, Shenton A, Ferner R, Wallace AJ, Huson SM, Ramsden RT, Evans DG.
    Clin Genet; 2010 Feb 20; 77(2):163-70. PubMed ID: 19968670
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques.
    Andreutti-Zaugg C, Scott RJ, Iggo R.
    Cancer Res; 1997 Aug 01; 57(15):3288-93. PubMed ID: 9242462
    [Abstract] [Full Text] [Related]

  • 16. Alport syndrome. Molecular genetic aspects.
    Hertz JM.
    Dan Med Bull; 2009 Aug 01; 56(3):105-52. PubMed ID: 19728970
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A point mutation associated with a severe phenotype of neurofibromatosis 2.
    MacCollin M, Braverman N, Viskochil D, Ruttledge M, Davis K, Ojemann R, Gusella J, Parry DM.
    Ann Neurol; 1996 Sep 01; 40(3):440-5. PubMed ID: 8797533
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.